AlloVir (NASDAQ:ALVR) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

AlloVir (NASDAQ:ALVRGet Rating) posted its earnings results on Thursday. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04, Fidelity Earnings reports.

AlloVir Trading Up 19.0 %

Shares of NASDAQ ALVR opened at $7.76 on Friday. The business has a fifty day simple moving average of $4.50 and a 200 day simple moving average of $5.97. The firm has a market capitalization of $507.66 million, a price-to-earnings ratio of -2.57 and a beta of 1.62. AlloVir has a one year low of $3.17 and a one year high of $26.41.

Analyst Ratings Changes

Several research firms recently weighed in on ALVR. SVB Leerink reduced their target price on AlloVir from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, July 28th. Piper Sandler cut their price target on AlloVir from $55.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, May 18th.

Insider Activity at AlloVir

In other AlloVir news, CEO Diana Brainard sold 29,135 shares of the company’s stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $4.33, for a total value of $126,154.55. Following the sale, the chief executive officer now directly owns 492,165 shares in the company, valued at $2,131,074.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Beek Jeroen B. Van sold 15,262 shares of the stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $4.40, for a total transaction of $67,152.80. Following the sale, the insider now owns 389,526 shares in the company, valued at $1,713,914.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Diana Brainard sold 29,135 shares of the stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $4.33, for a total value of $126,154.55. Following the sale, the chief executive officer now owns 492,165 shares in the company, valued at approximately $2,131,074.45. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,571 shares of company stock worth $225,167. 54.22% of the stock is owned by corporate insiders.

Institutional Trading of AlloVir

Several large investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of AlloVir by 2.9% during the first quarter. BlackRock Inc. now owns 2,230,919 shares of the company’s stock worth $15,059,000 after purchasing an additional 62,747 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of AlloVir by 27.7% during the first quarter. JPMorgan Chase & Co. now owns 763,908 shares of the company’s stock valued at $5,157,000 after acquiring an additional 165,711 shares during the period. Federated Hermes Inc. acquired a new position in shares of AlloVir during the first quarter valued at $860,000. Goldman Sachs Group Inc. lifted its stake in shares of AlloVir by 16.7% during the first quarter. Goldman Sachs Group Inc. now owns 108,104 shares of the company’s stock valued at $730,000 after acquiring an additional 15,495 shares during the period. Finally, Swiss National Bank lifted its stake in AlloVir by 7.5% in the first quarter. Swiss National Bank now owns 84,800 shares of the company’s stock valued at $572,000 after buying an additional 5,900 shares during the period. Institutional investors own 38.73% of the company’s stock.

About AlloVir

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Read More

Earnings History for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.